Skip to main content

Advertisement

Table 1 Anti-tumor activities of various ribosome-inactivating proteins (RIPs)

From: Anti-tumor activities and apoptotic mechanism of ribosome-inactivating proteins

RIP Tumor type Tested cell line(s)
Type I
 Trichosanthin Breast cancer MDA-MB-231a and MCF-7 [5]
Lymphoma CEM, Hut-78, Raji, and Daudi [12]
Cervical cancer HeLa [37]; Caski [38]
Choriocarcinoma JAR and BeWo [39]
Colon cancer CT-26 [40]; LoVo [41]
Hepatoma HepG2 [42]
Leukemia Molt-4 and Jurkat [12]; K562 [43]
Lung cancer 3LLa [44]
Melanoma B16 [45]
Nasopharyngeal cancer CNE1a and CNE2a [46]; CNE2 [47]
Prostate cancer RM-1 [48]
Gastric cancer MCG803 [49]
 α-Momorcharin Breast cancer MCF-7, EMT-6a, and MDA-MB-231a [11]
Colon cancer SW480 and SW620 [50]
Epidermoid A431 and Hep-2 [50]
Hepatoma Hep G2 and SMMC-7721 [50]
Lung cancer NCI-H460 and A549 [50]
Melanoma B16, M14, SK-MEL-28, and A2058 [50]
Nasopharyngeal cancer CNE2 and HONE1 [51]
 Momordica anti-HIV protein of 30 kDa Bladder cancer 5637 [52]
Breast cancer MDA-MB-231a [6]; BT20 [53]; MCF-7 [54]
Epidermoid A431 [53]
Glioma U87MG [53]
Hepatoma Hep G2a [27]; Hep-3B [53]
Melanoma Malme-3M [53]
Myeloma U266 [53]
Neuroblastoma SK-N-SH [53]
Prostate cancer DU145 [53]
Lung cancer A549 [55]
 Cucurmosin Lung cancer A549 [13]
Melanoma B16 [13]
Hepatoma HepG2a [28]
Leukemia NB4 [14]; K562a [56]
Myeloma RPM18226 [57]
Pancreatic cancer BxPC-3 [58]; SW-1990 [59]; PANC-1a [60]; CFPAC-1 [61]
 Saporin Leukemia NALM-6a [22]; HSB-2a [23]; CCRF CEMa [24]
Glioma U87MG [62]
Lymphoma Ramos, Rajia, Daudi, DOHH-2, and Granta 519, SUDHL-4 [21]; HDLM2, KM/H2, and L428 [63]
Neuroblastoma SK-N-MCa [64]
Ovarian cancer PA-1a [64]
Melanoma SK-Mel-1a [64], SK-Mel-28 [65]
Pancreatic cancer BxPC-3a [66]
Prostate cancer LNCaPa, CWR22Rv1, and DU145 [67]; PC-3a [68]
 Gelonin Breast cancer MDA-MB-231a, BT-474, SKBR3, MCF-7, and Eb1 [8]
Melanoma MDA-MB-435a, WM35, WM46, WM3211, WM1346, WM1361A, WM1366, WM793, WM983A, WM983B, MeWo, SB2, A375, A375M, SK-MEL-1, SK-MEL-3, SK-MEL-5, SK-MEL-24, SK-MEL-28, SK-MEL-32, WM35P2N1, AAB-527, and Sbcl2 [18]
Cervical cancer ME-180 [69]
Ovarian cancer SKOV3 [69]
Pancreatic cancer Capan-1, Capan-2, MIA-PaCa-2, AsPC-1, BxPC-3, and L3.6P1 [69]
Sarcoma HT-1080 [69]
Gastric cancer NCI N-87 [69]
Bladder cancer T-24a [69]; RT112a [70]
Epidermoid A431 [71]
Glioma U87 MG [69]; 9L [72]
Prostate cancer PC-3 [72]
Colon cancer HT-29a [71]; CT26a and LS174T [72]
Leukemia NALM-6a [25]; HL-60 [73]
Lung cancer Calu-3 [69]; A549a, H1975, and HCC827 [74]
Lymphoma Rec-1a and NUDHL-1a [25]; Minoa, JeKo-1, SP53 [26]; OCI-Ly3, OCI-Ly10a, SUDHL-4, and SUDHL-6 [75]
 Marmorin Breast cancer MCF-7a and MDA-MB-231a [10]
 α-Sarcin Astrocytoma 251-MG [76]
Breast cancer MCF-7 [76]
Glioma RuGli [76]
Pancreatic cancer Patu II [76]
Bladder cancer EJ [77]
Colon cancer HT29 and BCS-TC2 [76]; SW1222 [78]
Sarcoma HT-1080 [76]; S-180 [79]; RD [80]
 Curcin Lung cancer NCL-H446 [81]
Gastric cancer SGC-7901 [81]
Sarcoma S-180 [82]
 α-Luffin Breast cancer MCF-7 [83]
Choriocarcinoma JEG-3 [83]
Hepatoma HepG2 [83]
 MCP30 Prostate cancer LNCaP, PC-3, and PIN [84]
 Gelonium anti-HIV protein of 31 kDa Breast cancer MDA-MB-231a [6]
Type II
 Riproximin Breast cancer MCF-7 and MDA-MB-231 [62]
Larynx cancer Hep2 [62]
Leukemia AR230, CML-T1, HL-60, LAMA84, SKW-3, K562, and BV173 [62]
Lung cancer NCI-H460 and Lewisa [62]
Pancreatic cancer ASMLb [62]
Prostate cancer PC-3 [62]
Sarcoma Saos-2 [62]
Cervical cancer KB-3-1a [62]; HeLa [85]
Colon cancer HT-29, CC531b, and CT-26a [62]; HCT116 [86]
 Abrus agglutinin Hepatoma HepG2a [29]
 Momordica charantia lectin Nasopharyngeal cancer CNE1 and CNE2 [35]
 Articulatin-D Leukemia Jurkat, Molt-4, and HL-60 [15]
Lymphoma U937 and Raji [15]
 Mistletoe lectin I Leukemia NALM-6 [87]
 Foetidissimin II Cervical cancer HeLa [88]
Leukemia TF-1a [88]
 Ebulin I & Nigrin b Cervical cancer HeLa [89]
  1. aCell lines that have been studied in mouse.
  2. bCell lines that have been studied in rat.